Phase III Multicentric IIL Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Treatment of Patients With Stage II-IV Follicular Lymphoma
Phase III Multicentric IIL Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Treatment of Patients With Stage II-IV Follicular Lymphoma
The purpose of this study is to define an improvement and theassessment of the Time to Treatment Failure in patients randomized in three different arms:
R-CVP vs R-CHOP vs R-FM.
Assessment of Overall Survival (OS)in patients treated with R-CVP, R-CHOP and R-FM. -Assessment of Progression Free Survival (PFS)in patients treated with R-CVP, R-CHOP - Assessment of Duration of Response (DR)in patients treated with R-CVP, R-CHOP and R-FM. - Assessment of Response Rate(RR) in patients treated with R-CVP, R-CHOP and R-FM. - Assessment of molecular Response Rate in patients treated with R-CVP, R-CHOP and R-FM. - Assessment of toxicity of R-CVP, R-CHOP, R-FM treatments.
Inclusion Criteria:
Histological DIAGNOSIS of B cell follicular lymphoma
ECOG performance status 0-2
Age range 18-75
Ann Arbor Stage: II-IV
Assessment of pathology with diagnostics biopsy
Presence of one of these criteria:
LVEF > 50%
Normal hepatic (bilirubin < 1.5 mg/dl) and renal functionality (creatinin < 2 mg/dl). If there is a lymphoma it's allow values of bilirubin > 1.5 mg/dl and of creatinin > 2mg/dl
No previous treatment for follicolar lymphoma unless RT-IF
Lifetime > 6 mounth
Absence of HbsAg, HCV e HIV
Negative Coombs Test
Negative pregnant test
Cotracceptive method during the treatment and the follow three months
Formal written consent
Ability to follow the patients after the treatment for follow up
Exclusion Criteria:
Camposanpiero (PD), Italy
Reggio Calabria, Italy